Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience

This publication has 16 references indexed in Scilit:

• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
  New England Journal of Medicine, 2017
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  The Lancet Oncology, 2016
• The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
  The Lancet Haematology, 2016
• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  Blood, 2016
• American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
  Transplantation and Cellular Therapy, 2015
• Guidelines for determination of the number of prior lines of therapy in multiple myeloma
  Blood, 2015
• IMWG consensus on risk stratification in multiple myeloma
  Leukemia, 2013
• Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry
  Transplantation and Cellular Therapy, 2011
• Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
  Bone Marrow Transplantation, 2008
• Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
  New England Journal of Medicine, 2003